Lagevrio (Molnupiravir)

Brand Options

arrow pointer

Brand Name : Lagevrio

Marketing Authorization Holder : Merck

Prescription Required

 
 
No Generic Medicine available for this medicine.

Product Details

Lagevrio

Information about Lagevrio (Molnupiravir)

Lagevrio, also known as Molnupiravir, is an antiviral medication designed to treat COVID-19. It works by introducing errors into the viral RNA during replication, which helps to inhibit the virus's ability to multiply and spread.

Product Highlights

  • Indicated for mild to moderate COVID-19 in adults at high risk of progressing to severe disease.

Key Ingredient

  • Molnupiravir

Key Benefits

  • Aims to lower the likelihood of severe illness and hospitalization.
  • Oral formulation allows for easy and timely treatment initiation.
  • Specifically designed to inhibit RNA viruses, potentially reducing viral load.

Direction of Use

  • Typically, the recommended dose is 800 mg taken every 12 hours for 5 days, initiated as soon as possible after diagnosis and within 5 days of symptom onset.
  • Swallow capsules whole with or without food.

Safety Concerns

  • May include nausea, diarrhea, and headaches. Monitoring for serious adverse reactions is advised.
  • Not recommended for use during pregnancy; contraception should be used during treatment.

Avoid Lagevrio (Molnupiravir) If

  • You are pregnant or breastfeeding.
  • You have a known hypersensitivity to Molnupiravir or any component of the formulation.
  • You are currently taking medications that may interact negatively with Molnupiravir.


Image Image Image Image